{"id":"NCT00717860","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)","officialTitle":"A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2008-07-18","resultsPosted":"2011-08-26","lastUpdate":"2017-03-23"},"enrollment":121,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Fungal Infection"],"interventions":[{"type":"DRUG","name":"caspofungin acetate","otherNames":[]},{"type":"DRUG","name":"Comparator: Micafungin sodium","otherNames":[]}],"arms":[{"label":"Caspofungin","type":"EXPERIMENTAL"},{"label":"Micafungin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.","primaryOutcome":{"measure":"Number of Participants With a Significant Drug-related Adverse Experience","timeFrame":"1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis","effectByArm":[{"arm":"Caspofungin","deltaMin":3,"sd":null},{"arm":"Micafungin","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23052987"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":60},"commonTop":["Aspartate aminotransferase increased","Alanine aminotransferase increased","Blood alkaline phosphatase increased","Constipation","Headache"]}}